Long-term safety and efficacy of add-on cannabidiol for treatment of seizures associated with tuberous sclerosis complex in an open-label extension

被引：0
|
作者：
Kwan, Patrick [1 ,2 ]
Thiele, Elizabeth A. [3 ]
Bebin, E. Martina [4 ]
Filloux, Francis [5 ]
Jansen, Floor E. [6 ]
Loftus, Rachael [7 ]
Sahebkar, Farhad [8 ]
Sparagana, Steven [9 ,10 ]
Wheless, James [11 ,12 ]
机构：
[1] Monash Univ, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[5] Univ Utah, Sch Med, Salt Lake City, UT USA
[6] Univ Med Ctr, Brain Ctr, Utrecht, Netherlands
[7] GW Res Ltd, Cambridge, England
[8] Greenwich Biosci Inc, Carlsbad, CA USA
[9] Scottish Rite Children, Dallas, TX USA
[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[11] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA
[12] Le Bonheur Childrens Hosp, Memphis, TN USA
来源：
EPILEPSIA | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
135
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [1] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC) in an Open-Label Extension (OLE) Trial (GWPCARE6)
    Wheless, J.
    Bebin, E.
    Filloux, F.
    Kwan, P.
    Jansen, F.
    Loftus, R.
    Sahebkar, F.
    Sparagana, S.
    Thiele, E.
    ANNALS OF NEUROLOGY, 2021, 90 : S129 - S130
  • [2] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC) in an Open-Label Extension (OLE) Trial (GWPCARE6)
    Wheless, James
    Bebin, E. Martina
    Filloux, Francis
    Kwan, Patrick
    Jansen, Floor E.
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Thiele, Elizabeth
    NEUROLOGY, 2021, 96 (15)
  • [3] Long-term safety and efficacy of add-on cannabidiol for tuberous sclerosis complex-associated seizures: 3-year results from an open-label extension trial
    Sahebkar, F.
    Thiele, E. A.
    Bebin, E. M.
    Filloux, F.
    Jansen, F. E.
    Kwan, P.
    Loftus, R.
    Sparagana, S.
    Lawson, J.
    Wheless, J.
    EPILEPSIA, 2023, 64 : 289 - 290
  • [4] Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    EPILEPSIA, 2022, 63 (02) : 426 - 439
  • [5] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE)
    Thiele, Elizabeth
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Lawson, John
    Wheless, James
    NEUROLOGY, 2023, 100 (17)
  • [6] Long-term safety and efficacy of add-on cannabidiol (CBD) for seizures associated with tuberous sclerosis complex (TSC): 3-year results from GWPCARE6 open-label extension (OLE)
    Wheless, James
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor E.
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Lawson, John
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [7] Efficacy and Safety of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC) in Pediatric Patients Enrolled in a Phase 3 Trial With an Open-Label Extension (OLE)
    Thiele, E.
    Lawson, J.
    Kotulska, K.
    Sahebkar, F.
    Greco, T.
    Saurer, T.
    ANNALS OF NEUROLOGY, 2023, 94 : S57 - S57
  • [8] Efficacy and Safety of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC) in Pediatric Patients Enrolled in a Phase 3 Trial With an Open-Label Extension (OLE)
    Thiele, E.
    Lawson, J.
    Kotulska, K.
    Sahebkar, F.
    Greco, T.
    Saurer, T.
    ANNALS OF NEUROLOGY, 2023, 94 : S55 - S55
  • [9] Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an open-label, Extension Trial
    Halford, Jonathan
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawsky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    VanLandingham, Kevan
    NEUROLOGY, 2019, 92 (15)
  • [10] Long- term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE)
    Thiele, E.
    Bebin, E.
    Filloux, F.
    Jansen, F.
    Kwan, P.
    Loftus, R.
    Sahebkar, F.
    Sparagana, S.
    Lawson, J.
    Wheless, J.
    ANNALS OF NEUROLOGY, 2023, 94 : S53 - S53
12345